Thinking of trading METLIFE?
- 1. The most common reason investors are drawn to Metlife stock is because it offers a strong 3. 7 percent dividend for income-minded investors, and a solid forward price-earnings ratio that suggests the stock offers good value to investors looking for a deal. 2. Another reason to invest in Metlife stock is its valuation, which investors find very attractive relative to its tangible book value.
Trading CFDs involves significant risk of loss
How would you like to trade METLIFE?
- Tight spreads & reliable execution
- 70+ pre-installed indicators
- Custom indicators
- 26 time frames
- Live Sentiment data
- Chart trading
- Advanced Take Profit & Stop Loss
- Depth of Market
Trading CFDs involves significant risk of loss
- Vast selection of strategies to copy
- Efficient risk management
- Can start and stop copying at your will
- Flexible allocation of funds
- Detailed performance reports
- Full transparency & access to historical data
Copy link
Trading CFDs involves significant risk of loss
For beginners:
- Great choice of available cBots for various trading strategies and risk tolerance levels
- Simple Plug and Play functionality
For advanced traders:
- Ability to create your own cBot or custom indicator
Trading CFDs involves significant risk of loss
Trade METLIFE with Fondex. Our CFD trading platform is engineered to provide you with optimal execution speed while allowing you to access 3 different trading methods on the same interface.
1. Met life and the whole insurance industry is highly dependent on interest rates therefore, Money managers believe that investors should be mindful of interest rates when considering Metlife stock because of it will influence a buying decision not always positively but negatively as well. 2. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. However, with a negative profit growth of -2. 5% expected over the next couple of years, near-term growth certainly doesn't appear to be a driver for a buy decision for MetLife.
Risk Disclaimer Fondex provides this content/feature as no more than information. In particular, no advice is intended to be provided or to be relied on as provided nor endorsed by Fondex, nor any solicitation or incentive provided to subscribe for or sell or purchase any financial instrument or to join and/or terminate any of the trading strategies. The Investor is solely responsible for the choice of the signal provider, choice of trading strategy, the choice whether to sell or purchase any financial instrument on his/her trading account and monitoring of the trading activities. All trading or investments you make must be pursuant to your own unprompted and informed self-directed position. Please keep in mind that past performance is no guarantee of future results.
For more information, please view the 'Risk Disclosure'